# Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery

> **NCT00049322** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00049322
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-09-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049322

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049322, "Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed With Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00049322. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*